Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .
The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
The Probucol Quantitative Regression Swedish Trial ( PQRST ) investigated the effect of the lipid lowering and antioxidant drug probucol on the development of atherosclerosis in humans . 303 hypercholesterolemic patients were r and omized to receive either probucol or placebo , in combination with dietary advice and cholestyramine for a three-year period . Probucol was not found to effect progression regression of femoral atherosclerosis significantly as assessed by quantitative arteriography . To evaluate the effectiveness of probucol as an antioxidant during the study period , detailed analyses were performed on 42 of the r and omized patients . During the trial , probucol-treated patients ( n = 26 ) had 15 % lower total cholesterol ( P < 0.01 ) and 35 % lower high density lipoprotein ( HDL ) cholesterol ( P < 0.0001 ) compared with controls ( n = 16 ) . Low density lipoprotein ( LDL ) from probucol treated individuals was more resistant to oxidation by Cu2 + as determined by the lag phase for the formation of conjugated dienes ( 220 + /- 8 vs. 82 + /- 7 min ( mean + /- S.E ) ) , showed a 13 times lower formation of lipid peroxides , a 97 % reduction in macrophage degradation and close to 90 % less decrease in LDL receptor binding following oxidation as compared with controls ( P < 0.001 for all differences ) . The results demonstrate that although probucol provided a significant protection against Cu(2+)-induced oxidative modification of LDL , it lacked effect on the development of femoral atherosclerosis . The relevance of these observations for the proposed role of lipid oxidation in atherosclerosis is discussed
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .